| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.
Key Highlights
U.S. Provisional Patents filed expanding HT-001's therapeutic reach.
Indications covered:
Drug-Induced Hypersensitivity Syndrome
Radiotherapy-Induced Rash
Dermatological Conditions Associated with MENIN Inhibitor Therapy
MENIN inhibitors are an emerging oncology class with significant promise in acute leukemias and select solid tumors, but treatment-limiting rashes remain a major clinical challenge.
HT-001 designed to improve tolerability of cancer therapies by addressing dermatological side effects, potentially enabling patients to remain on therapy longer.
NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and inflammatory conditions, today announced the expansion of its intellectual property portfolio for HT-001, its lead topical therapeutic candidate. The Company has filed multiple U.S. Provisional Patent Applications covering novel dermatological indications, broadening the commercial and clinical potential of HT-001.
Posted In: HOTH
